Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 226
interventional 218
Observational 7
Registry 1

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 91
Drug|Other 24
Biological|Drug|Other 15
Drug|Other|Procedure|Radiation 12
Biological 11
Biological|Drug 8
Biological|Drug|Procedure|Radiation 7
Biological|Other 6
Biological|Drug|Other|Procedure|Radiation 5
Drug|Procedure 5
Drug|Procedure|Radiation 5
Biological|Drug|Radiation 3
Biological|Other|Procedure 3
Drug|Genetic|Other 3
Biological|Drug|Other|Procedure 2
Biological|Procedure|Radiation 2
Biological|Device|Drug|Procedure|Radiation 1
Biological|Drug|Genetic|Other 1
Biological|Drug|Genetic|Other|Procedure 1
Biological|Drug|Other|Radiation 1
Biological|Drug|Procedure 1
Biological|Genetic|Other 1
Biological|placebo 1
Biological|Radiation 1
Dietary Supplement|Drug 1
Dietary Supplement|Other 1
Drug|Genetic|Other|Procedure|Radiation 1
Drug|Genetic|Procedure|Radiation 1
Drug|Other|Procedure 1
Drug|placebo 1
Drug|Radiation 1
Procedure 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 162
France 5
United States|Canada 5
United States|Italy 5
United Kingdom 4
United States|Germany|Italy 4
China 3
Korea, Republic of 3
Germany 2
Japan 2
Poland 2
United States|Denmark|Germany 2
Canada|Germany 1
Greece 1
Hong Kong 1
Italy 1
NA 1
United Kingdom|Australia 1
United States|Argentina|Australia|Belgium|Brazil|Canada|China|Colombia|Czechia|France|Germany|Greece|Hungary|Ireland|Israel|Italy|Korea, Republic of|Mexico|Netherlands|Poland|Portugal|Russian Federation|Spain|Sweden|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia|Belgium|Czechia|France|Germany|Greece|Italy|Netherlands|Poland|Spain|Sweden|United Kingdom 1
United States|Australia|Canada|France|Germany|Greece|Italy|Spain|United Kingdom 1
United States|Australia|France|Poland 1
United States|Canada|Sweden|United Kingdom 1
United States|Denmark 1
United States|France 1
United States|France|Germany|Italy|Poland|United Kingdom 1
United States|Germany 1
United States|Italy|United Kingdom 1
United States|Netherlands|United Kingdom 1
United States|Puerto Rico|South Africa 1
United States|United Kingdom 1

Sites per Study

Site_count Study_Count
1 106
2 25
3 9
4 8
5 12
6 4
7 6
8 4
9 1
10 6
11 11
12 3
13 3
14 1
15 1
16 2
18 1
19 2
20 2
22 1
23 1
25 1
30 1
41 1
48 1
49 1
69 1
80 1
84 1
164 1

Phase

Phase Study_Count
Phase 2 95
Phase 1 61
Phase 1/Phase 2 37
N/A 10
Phase 3 10
Early Phase 1 4
Phase 4 1

Number of Arms

Number_of_Arms Count_of_Studies
1 164
2 26
3 10
7 1
10 1
11 2
NA 14

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.3 Phase.4
Min. 16.0 5.00 2.0000 5.00000 7.00000 62.00 17
1st Qu. 26.5 56.75 18.0000 30.00000 31.00000 175.75 17
Median 31.5 71.50 30.0000 44.00000 42.00000 215.50 17
Mean 28.0 112.80 43.5082 72.18919 54.56989 269.90 17
3rd Qu. 33.0 170.50 48.0000 102.00000 63.00000 362.50 17
Max. 33.0 300.00 210.0000 403.00000 210.00000 700.00 17

Trial Group Type

group_type Group_Count
Experimental 264
NA 14
Active Comparator 12
Other 7
No Intervention 2

Intervention Model

intervention_model Study_Count
Single Group Assignment 179
Parallel Assignment 28
NA 6
Sequential Assignment 5

Primary Purpose

primary_purpose Study_Count
Treatment 208
Supportive Care 3
Basic Science 2
Prevention 2
NA 2
Other 1

Observational Studies

Studies by Country

Country Study_Count
United States 6
Italy 1

Sites per Study

Site_count Study_Count
1 4
2 1
20 1
207 1

Enrollment Metrics

Measure Observational
Min 153.0000
1st Qu 245.0000
Median 550.0000
Mean 835.5714
3rd Qu 828.0000
Max 3000.0000

Observation Model

observational_model Study_Count
Case-Only 2
Cohort 2
NA 2
Family-Based 1

Time Perspective

time_perspective Study_Count
Other 3
Prospective 2
NA 2

Registries

Studies by Country

Country Study_Count
United States 1

Sites per Study

Site_count Study_Count
1 1

Enrollment Metrics

Measure Registries
Min 10000
1st Qu 10000
Median 10000
Mean 10000
3rd Qu 10000
Max 10000

Registry Model

observational_model Study_Count
Cohort 1

Time Perspective

time_perspective Study_Count
Prospective 1

Follow-up

target_duration Study_Count
10 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03364231 Study to Assess the Efficacy and Safety of Umbralisib in Patients With Non-Follicular Indolent Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT03364231 Recruiting TG Therapeutics, Inc. 2020-11-01
NCT03410901 TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas https://ClinicalTrials.gov/show/NCT03410901 Recruiting Stanford University 2020-10-09
NCT03820817 Rifaximin in Patients With Monoclonal Gammopathy https://ClinicalTrials.gov/show/NCT03820817 Recruiting Emory University 2020-11-30
NCT03335098 Study of VTD in Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT03335098 Recruiting Seoul National University Hospital 2020-12-31
NCT03333486 Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer https://ClinicalTrials.gov/show/NCT03333486 Recruiting Roswell Park Cancer Institute 2022-09-06
NCT03332173 Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström’s Macroglobulinemia (WM) https://ClinicalTrials.gov/show/NCT03332173 Active, not recruiting BeiGene 2020-12-31
NCT03314974 Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders https://ClinicalTrials.gov/show/NCT03314974 Recruiting Masonic Cancer Center, University of Minnesota 2025-01-10
NCT03277729 A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas https://ClinicalTrials.gov/show/NCT03277729 Recruiting Fred Hutchinson Cancer Research Center 2022-11-16
NCT03225716 A Study of Ulocuplumab And Ibrutinib in Symptomatic Patients With Mutated CXCR4 Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT03225716 Active, not recruiting Dana-Farber Cancer Institute 2021-01-31
NCT03192397 Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT03192397 Recruiting Roswell Park Cancer Institute 2021-07-01
NCT03187262 A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia https://ClinicalTrials.gov/show/NCT03187262 Active, not recruiting Dana-Farber Cancer Institute 2021-01-31
NCT03162536 A Study of ARQ 531 in Patients With Selected Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03162536 Recruiting ArQule 2021-12-31
NCT03133221 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin’s Lymphoma After Autologous Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT03133221 Recruiting University of Maryland, Baltimore 2021-03-31
NCT03053440 A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström’s Macroglobulinemia (WM) https://ClinicalTrials.gov/show/NCT03053440 Active, not recruiting BeiGene 2021-06-30
NCT03037645 Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers https://ClinicalTrials.gov/show/NCT03037645 Recruiting Sunesis Pharmaceuticals 2020-12-31
NCT03019666 Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL https://ClinicalTrials.gov/show/NCT03019666 Recruiting Masonic Cancer Center, University of Minnesota 2020-09-30
NCT03015896 Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03015896 Recruiting Ohio State University Comprehensive Cancer Center 2020-04-30
NCT03010358 Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03010358 Active, not recruiting OHSU Knight Cancer Institute 2022-02-28
NCT02991638 Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers https://ClinicalTrials.gov/show/NCT02991638 Recruiting The University of Hong Kong 2020-12-31
NCT02962401 Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT02962401 Active, not recruiting French Innovative Leukemia Organisation 2020-08-31
NCT02952508 Study of CLR 131 in Relapsed or Refractory Select B-Cell Malignancies (CLOVER-1) https://ClinicalTrials.gov/show/NCT02952508 Recruiting Cellectar Biosciences, Inc. 2020-07-31
NCT02950220 Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02950220 Completed Ohio State University Comprehensive Cancer Center 2018-11-19
NCT02933320 BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia https://ClinicalTrials.gov/show/NCT02933320 Recruiting Cancer Research UK 2022-01-31
NCT02916979 Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators’ Expression in Allogeneic SCT Using FluBuATG https://ClinicalTrials.gov/show/NCT02916979 Active, not recruiting Dartmouth-Hitchcock Medical Center 2020-12-31
NCT02722668 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep https://ClinicalTrials.gov/show/NCT02722668 Recruiting Masonic Cancer Center, University of Minnesota 2028-05-31
NCT02677324 Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia https://ClinicalTrials.gov/show/NCT02677324 Active, not recruiting Dana-Farber Cancer Institute 2020-03-31
NCT02669017 Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) https://ClinicalTrials.gov/show/NCT02669017 Completed ADC Therapeutics S.A. 2019-02-21
NCT02661035 Allo HSCT Using RIC for Hematological Diseases https://ClinicalTrials.gov/show/NCT02661035 Recruiting Masonic Cancer Center, University of Minnesota 2023-03-31
NCT02652715 Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02652715 Completed Mayo Clinic 2018-12-21
NCT02604511 Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom’s Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing https://ClinicalTrials.gov/show/NCT02604511 Active, not recruiting Dana-Farber Cancer Institute 2021-02-28
NCT04116437 Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment https://ClinicalTrials.gov/show/NCT04116437 Recruiting BeiGene 2022-09-30
NCT02566265 Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients https://ClinicalTrials.gov/show/NCT02566265 Completed Yale University 2017-10-31
NCT01381692 Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma https://ClinicalTrials.gov/show/NCT01381692 Active, not recruiting National Cancer Institute (NCI) 2014-07-23
NCT02432235 Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02432235 Completed ADC Therapeutics S.A. 2019-10-24
NCT02400437 Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT02400437 Completed Dana-Farber Cancer Institute 2019-11-30
NCT02371148 Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia’s https://ClinicalTrials.gov/show/NCT02371148 Active, not recruiting Fondazione Italiana Linfomi ONLUS 2017-11-30
NCT02363439 Extension Study of IMO-8400 in Patients With Waldenström’s Macroglobulinemia Who Completed Study 8400-401 https://ClinicalTrials.gov/show/NCT02363439 Completed Idera Pharmaceuticals, Inc. 2016-12-31
NCT02362035 ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies https://ClinicalTrials.gov/show/NCT02362035 Active, not recruiting Acerta Pharma BV 2021-05-31
NCT02339922 Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02339922 Active, not recruiting University of Washington 2025-01-06
NCT02332980 Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas https://ClinicalTrials.gov/show/NCT02332980 Recruiting Mayo Clinic 2021-01-05
NCT02302469 Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia https://ClinicalTrials.gov/show/NCT02302469 Completed University Hospital, Lille 2017-03-31
NCT02257242 Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma https://ClinicalTrials.gov/show/NCT02257242 Recruiting Brown University 2020-12-31
NCT02242045 Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Adults With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas or Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT02242045 Completed Gilead Sciences 2014-12-25
NCT02213913 Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas https://ClinicalTrials.gov/show/NCT02213913 Recruiting University of Chicago 2020-07-29
NCT02180724 An Open-label, Phase 2 Study of Acalabrutinib in Subjects With Waldenström Macroglobulinemia https://ClinicalTrials.gov/show/NCT02180724 Active, not recruiting Acerta Pharma BV 2018-02-28
NCT02165397 Ibrutinib With Rituximab in Adults With Waldenström’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT02165397 Completed Pharmacyclics LLC. 2019-11-07
NCT02153580 Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia https://ClinicalTrials.gov/show/NCT02153580 Recruiting City of Hope Medical Center 2021-12-31
NCT02071888 Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors https://ClinicalTrials.gov/show/NCT02071888 Completed Calithera Biosciences, Inc 2016-04-30
NCT01314014 Imexon for Relapsed Follicular and Aggressive Lymphomas https://ClinicalTrials.gov/show/NCT01314014 Completed University of Rochester 2013-03-31
NCT01282424 Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas https://ClinicalTrials.gov/show/NCT01282424 Completed Gilead Sciences 2018-05-02
NCT01273766 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01273766 Completed Wake Forest University Health Sciences 2012-03-31
NCT02049541 Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT02049541 Active, not recruiting Ohio State University Comprehensive Cancer Center 2018-09-12
NCT04018248 BR101801 in Adult Patients With Advanced Hematologic Malignancies( Phase I) https://ClinicalTrials.gov/show/NCT04018248 Recruiting Boryung Pharmaceutical Co., Ltd 2023-12-31
NCT04273139 Ibrutinib + Venetoclax in Untreated WM https://ClinicalTrials.gov/show/NCT04273139 Recruiting Dana-Farber Cancer Institute 2023-06-01
NCT03479268 Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03479268 Recruiting City of Hope Medical Center 2022-04-01
NCT01962636 Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases https://ClinicalTrials.gov/show/NCT01962636 Recruiting Masonic Cancer Center, University of Minnesota 2023-10-31
NCT01959477 Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01959477 Completed Case Comprehensive Cancer Center 2015-01-31
NCT01955499 Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01955499 Active, not recruiting National Cancer Institute (NCI) 2021-12-31
NCT01815749 Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01815749 Active, not recruiting City of Hope Medical Center 2020-10-31
NCT01805375 A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies https://ClinicalTrials.gov/show/NCT01805375 Completed Cancer Research UK 2017-12-14
NCT01805037 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas https://ClinicalTrials.gov/show/NCT01805037 Active, not recruiting Northwestern University 2021-01-31
NCT01804686 A Long-term Extension Study of PCI-32765 (Ibrutinib) https://ClinicalTrials.gov/show/NCT01804686 Enrolling by invitation Janssen Research & Development, LLC 2026-12-31
NCT01789255 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01789255 Completed National Cancer Institute (NCI) 2014-03-31
NCT01788020 Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT01788020 Active, not recruiting University of Ulm 2018-11-30
NCT01760655 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01760655 Recruiting Thomas Jefferson University 2021-03-31
NCT01748721 MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT01748721 Completed Morphotek 2015-05-31
NCT01744912 Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT01744912 Completed TG Therapeutics, Inc. 2014-05-31
NCT01678443 Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT01678443 Active, not recruiting Fred Hutchinson Cancer Research Center 2011-04-11
NCT01658319 Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01658319 Completed Case Comprehensive Cancer Center 2015-02-28
NCT01647971 Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01647971 Completed TG Therapeutics, Inc. 2015-05-31
NCT01592981 Randomised Trial in Waldenstrom’s Macroglobulinaemia https://ClinicalTrials.gov/show/NCT01592981 Active, not recruiting University College, London 2017-03-31
NCT01588015 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01588015 Active, not recruiting City of Hope Medical Center 2021-11-30
NCT01567709 Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01567709 Completed National Cancer Institute (NCI) 2018-03-29
NCT01529827 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01529827 Completed Roswell Park Cancer Institute 2015-05-28
NCT01527045 Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01527045 Completed Fred Hutchinson Cancer Research Center 2018-10-31
NCT01523223 Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies https://ClinicalTrials.gov/show/NCT01523223 Completed Stanford University 2016-09-30
NCT01479842 Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT01479842 Active, not recruiting Ohio State University Comprehensive Cancer Center 2014-03-31
NCT01474681 Safety and Tolerability of HSC835 in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01474681 Completed Novartis 2016-10-03
NCT01470196 Carfilzomib, Rituximab and Dexamethasone in Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT01470196 Completed Dana-Farber Cancer Institute 2016-09-30
NCT01427881 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01427881 Completed Fred Hutchinson Cancer Research Center 2014-06-30
NCT01416428 Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01416428 Completed Amgen 2019-08-12
NCT01384513 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01384513 Recruiting Thomas Jefferson University 2020-12-31
NCT01351935 Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT01351935 Completed Celgene 2015-06-26
NCT01326702 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors https://ClinicalTrials.gov/show/NCT01326702 Completed National Cancer Institute (NCI) 2015-04-30
NCT04440059 A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia https://ClinicalTrials.gov/show/NCT04440059 Recruiting Beijing InnoCare Pharma Tech Co., Ltd. 2021-10-31
NCT04274738 A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom’s Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4 https://ClinicalTrials.gov/show/NCT04274738 Recruiting X4 Pharmaceuticals 2021-06-30
NCT04191187 Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT04191187 Recruiting H. Lee Moffitt Cancer Center and Research Institute 2022-12-31
NCT04115059 Dasatinib In Waldenström Macroglobulinemia https://ClinicalTrials.gov/show/NCT04115059 Recruiting Dana-Farber Cancer Institute 2022-03-01
NCT04062448 A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom’s Macroglobulinemia (WM) https://ClinicalTrials.gov/show/NCT04062448 Recruiting Janssen Pharmaceutical K.K. 2023-06-01
NCT04042376 A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom’s Macroglobulinemia (WM) https://ClinicalTrials.gov/show/NCT04042376 Recruiting Janssen Research & Development, LLC 2023-12-31
NCT03884998 Copanlisib and Nivolumab in Treating Participants With Richter’s Transformation or Transformed Indolent Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT03884998 Recruiting OHSU Knight Cancer Institute 2021-01-06
NCT03833180 A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03833180 Recruiting VelosBio Inc. 2021-03-31
NCT03771157 Serologic Response to a New Recombinant, Adjuvanted Herpes Zoster Vaccine in Patients With Chronic Lymphocytic Leukemia and Waldenström Macroglobulinemia Treated With First-Line BTK Inhibitors https://ClinicalTrials.gov/show/NCT03771157 Active, not recruiting University of Rochester 2019-08-28
NCT03740529 A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL https://ClinicalTrials.gov/show/NCT03740529 Recruiting Loxo Oncology, Inc. 2020-10-31
NCT03697356 R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT03697356 Recruiting Kosin University Gospel Hospital 2021-10-31
NCT03679455 A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1 https://ClinicalTrials.gov/show/NCT03679455 Recruiting Polish Myeloma Consortium 2019-04-30
NCT03674411 Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy https://ClinicalTrials.gov/show/NCT03674411 Recruiting Masonic Cancer Center, University of Minnesota 2023-07-31
NCT03630042 Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström’s Macroglobulinaemia https://ClinicalTrials.gov/show/NCT03630042 Recruiting University College, London 2021-03-31
NCT03620903 Efficacy of First Line B-RI for Treatment Naive Waldenström’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT03620903 Recruiting University of Ulm 2022-03-31
NCT03601819 Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders https://ClinicalTrials.gov/show/NCT03601819 Recruiting University of Michigan Rogel Cancer Center 2021-09-30
NCT03506373 Ibrutinib and Ixazomib Citrate in Treating Participants With Relapsed or Refractory Waldenstrom Macroglobulinemia https://ClinicalTrials.gov/show/NCT03506373 Recruiting Mayo Clinic 2025-05-01
NCT01261247 Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01261247 Active, not recruiting Mayo Clinic 2016-05-09
NCT01258998 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma https://ClinicalTrials.gov/show/NCT01258998 Completed National Cancer Institute (NCI) 2014-07-31
NCT01254578 Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers https://ClinicalTrials.gov/show/NCT01254578 Completed National Cancer Institute (NCI) 2012-11-09
NCT01251575 Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01251575 Completed Fred Hutchinson Cancer Research Center 2018-11-23
NCT01239875 Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01239875 Completed Mayo Clinic 2015-11-24
NCT01231919 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia https://ClinicalTrials.gov/show/NCT01231919 Completed National Cancer Institute (NCI) 2013-04-30
NCT01231412 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01231412 Completed Fred Hutchinson Cancer Research Center 2016-10-08
NCT01209871 Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma https://ClinicalTrials.gov/show/NCT01209871 Active, not recruiting M.D. Anderson Cancer Center 2020-02-20
NCT01198067 Pomalidomide in Treating Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia https://ClinicalTrials.gov/show/NCT01198067 Active, not recruiting M.D. Anderson Cancer Center 2021-10-31
NCT01177371 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01177371 Completed Case Comprehensive Cancer Center 2000-02-29
NCT01158274 RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT01158274 Completed National Cancer Institute (NCI) 2012-08-31
NCT01129193 AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma https://ClinicalTrials.gov/show/NCT01129193 Completed Ohio State University Comprehensive Cancer Center 2017-01-07
NCT01125293 Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT01125293 Active, not recruiting Dana-Farber Cancer Institute 2020-02-29
NCT01118689 Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia https://ClinicalTrials.gov/show/NCT01118689 Completed Millennium Pharmaceuticals, Inc. 2013-05-31
NCT01110135 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma https://ClinicalTrials.gov/show/NCT01110135 Completed University of Washington 2013-11-30
NCT01109069 Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT01109069 Completed Pharmacyclics LLC. 2019-04-26
NCT01076543 Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01076543 Completed National Cancer Institute (NCI) 2017-12-31
NCT01075321 Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01075321 Active, not recruiting Mayo Clinic 2015-02-28
NCT01008462 Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT01008462 Completed Fred Hutchinson Cancer Research Center 2018-06-30
NCT00976248 Everolimus (RAD001) in Primary Therapy of Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT00976248 Completed Dana-Farber Cancer Institute 2016-07-31
NCT00936611 LBH589 in Relapsed or Relapsed and Refractory Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT00936611 Active, not recruiting Dana-Farber Cancer Institute 2020-02-29
NCT00918333 Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00918333 Completed Mayo Clinic 2015-12-01
NCT00891072 Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT00891072 Completed National Cancer Institute (NCI) 2011-04-30
NCT00890747 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy https://ClinicalTrials.gov/show/NCT00890747 Completed National Cancer Institute (NCI) 2011-05-31
NCT00867529 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma https://ClinicalTrials.gov/show/NCT00867529 Completed Fred Hutchinson Cancer Research Center 2015-03-31
NCT00861510 A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT00861510 Completed National Institutes of Health Clinical Center (CC) 2012-10-19
NCT00856388 Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders https://ClinicalTrials.gov/show/NCT00856388 Completed Roswell Park Cancer Institute 2012-08-09
NCT00832234 Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia https://ClinicalTrials.gov/show/NCT00832234 Completed European Myeloma Network 2010-06-30
NCT02640287 Expression of Ku70/XRCC6 in Waldenström’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT02640287 Recruiting Central Hospital, Nancy, France 2019-11-02
NCT00811733 A Phase II Trial of Ofatumumab in Subjects With Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT00811733 Completed GlaxoSmithKline 2011-06-01
NCT00807677 A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00807677 Completed Millennium Pharmaceuticals, Inc. 2012-09-30
NCT00801281 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. https://ClinicalTrials.gov/show/NCT00801281 Completed Polish Lymphoma Research Group 2017-06-25
NCT03246906 Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation https://ClinicalTrials.gov/show/NCT03246906 Recruiting Fred Hutchinson Cancer Research Center 2022-08-15
NCT03147885 Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03147885 Recruiting Barbara Ann Karmanos Cancer Institute 2020-06-30
NCT01839916 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01839916 Completed University of Chicago 2018-08-31
NCT01614821 Ibrutinib (PCI-32765) in Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT01614821 Completed Dana-Farber Cancer Institute 2016-09-09
NCT00789776 Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer https://ClinicalTrials.gov/show/NCT00789776 Completed Fred Hutchinson Cancer Research Center 2017-05-31
NCT00783367 Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas https://ClinicalTrials.gov/show/NCT00783367 Active, not recruiting Abramson Cancer Center of the University of Pennsylvania 2012-11-14
NCT00777738 Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia https://ClinicalTrials.gov/show/NCT00777738 Completed Assistance Publique - Hôpitaux de Paris 2012-08-31
NCT00769288 FAU in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00769288 Completed National Cancer Institute (NCI) 2013-12-31
NCT00723099 Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer https://ClinicalTrials.gov/show/NCT00723099 Completed Fred Hutchinson Cancer Research Center 2018-07-31
NCT00720135 Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00720135 Completed City of Hope Medical Center 2014-07-31
NCT00719888 Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease https://ClinicalTrials.gov/show/NCT00719888 Recruiting Fred Hutchinson Cancer Research Center 2022-12-31
NCT00718419 A Study for Patients That Have Been Previously Been Treated in Waldenstrom’s Macroglobulinemia or Multiple Myeloma https://ClinicalTrials.gov/show/NCT00718419 Completed Eli Lilly and Company 2010-09-30
NCT00711828 Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00711828 Completed Mayo Clinic 2013-11-30
NCT00697346 Study of MLN8237 in Participants With Advanced Hematological Malignancies https://ClinicalTrials.gov/show/NCT00697346 Completed Takeda 2016-10-01
NCT00644189 Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00644189 Active, not recruiting Massachusetts General Hospital 2013-12-31
NCT00621452 Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00621452 Completed Fred Hutchinson Cancer Research Center 2014-01-31
NCT00608374 Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma https://ClinicalTrials.gov/show/NCT00608374 Completed National Cancer Institute (NCI) 2009-12-31
NCT00608361 Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery https://ClinicalTrials.gov/show/NCT00608361 Completed National Cancer Institute (NCI) 2014-08-31
NCT00601718 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00601718 Completed University of Washington 2010-06-30
NCT00566332 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia https://ClinicalTrials.gov/show/NCT00566332 Completed French Study Group on Chronic Lymphoid Leukemia 2009-09-30
NCT00546793 Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL https://ClinicalTrials.gov/show/NCT00546793 Completed Immunomedics, Inc. 2013-03-31
NCT00536601 High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors https://ClinicalTrials.gov/show/NCT00536601 Completed Roswell Park Cancer Institute 2018-07-09
NCT00499811 Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00499811 Completed National Cancer Institute (NCI) 2011-08-31
NCT00492050 Bortezomib and Rituximab for Patients With Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT00492050 Active, not recruiting M.D. Anderson Cancer Center 2021-02-28
NCT00481871 Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies https://ClinicalTrials.gov/show/NCT00481871 Completed Acrotech Biopharma LLC 2011-05-31
NCT00458731 Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma https://ClinicalTrials.gov/show/NCT00458731 Completed National Cancer Institute (NCI) 2013-12-31
NCT00438880 Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00438880 Completed Mayo Clinic 2010-10-31
NCT01093586 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01093586 Completed Case Comprehensive Cancer Center 2015-12-31
NCT00422799 Combination Bortezomib and Rituximab in Patients With Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT00422799 Completed Dana-Farber Cancer Institute 2015-10-09
NCT00422656 Perifosine in Patients With Relapsed/Refractory Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT00422656 Completed Dana-Farber Cancer Institute 2009-06-30
NCT00348985 PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00348985 Completed National Cancer Institute (NCI) 2010-01-31
NCT00293345 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00293345 Completed National Cancer Institute (NCI) 2012-10-31
NCT00290472 CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT00290472 Completed National Cancer Institute (NCI) 2010-04-30
NCT00281983 Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT00281983 Completed German CLL Study Group NA
NCT00273936 Trial of AVN-944 in Patients With Advanced Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00273936 Completed Vertex Pharmaceuticals Incorporated NA
NCT00250926 Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia https://ClinicalTrials.gov/show/NCT00250926 Completed Dana-Farber Cancer Institute 2007-03-31
NCT00244855 Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00244855 Completed Fred Hutchinson Cancer Research Center 2008-12-31
NCT00165295 Sildenafil Citrate in Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT00165295 Completed Dana-Farber Cancer Institute 2007-06-30
NCT00150462 Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT00150462 Completed Amgen 2009-10-31
NCT00146055 Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood https://ClinicalTrials.gov/show/NCT00146055 Completed University of Michigan Rogel Cancer Center 2004-11-30
NCT00142181 Phase II Study of Campath-1H Antibody to Treat Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT00142181 Completed Dana-Farber Cancer Institute 2005-10-31
NCT00142155 Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT00142155 Completed Dana-Farber Cancer Institute 2007-03-31
NCT00142129 Bortezomib (Velcade) in Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT00142129 Completed Dana-Farber Cancer Institute 2007-06-30
NCT00142116 Thalidomide and Rituximab in Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT00142116 Completed Dana-Farber Cancer Institute 2004-02-29
NCT00119392 Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00119392 Completed Fred Hutchinson Cancer Research Center 2009-07-31
NCT00118352 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00118352 Completed Fred Hutchinson Cancer Research Center 2010-07-31
NCT00118170 Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin’s Lymphoma With or Without Impaired Liver or Kidney Function https://ClinicalTrials.gov/show/NCT00118170 Completed National Cancer Institute (NCI) 2007-05-31
NCT00112593 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer https://ClinicalTrials.gov/show/NCT00112593 Completed Fred Hutchinson Cancer Research Center 2014-11-30
NCT00110071 Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00110071 Completed Fred Hutchinson Cancer Research Center 2011-06-30
NCT00105001 Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00105001 Completed Fred Hutchinson Cancer Research Center 2011-05-31
NCT00098891 MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00098891 Completed National Cancer Institute (NCI) 2008-03-31
NCT00096161 Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00096161 Completed Fred Hutchinson Cancer Research Center 2015-02-28
NCT00089271 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00089271 Completed National Cancer Institute (NCI) 2010-06-30
NCT00089011 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00089011 Completed Fred Hutchinson Cancer Research Center 2014-03-31
NCT00003416 S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT00003416 Completed Southwest Oncology Group 2000-08-31
NCT00003196 Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma https://ClinicalTrials.gov/show/NCT00003196 Completed Fred Hutchinson Cancer Research Center 2002-04-30
NCT00006251 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer https://ClinicalTrials.gov/show/NCT00006251 Completed Fred Hutchinson Cancer Research Center 2005-09-30
NCT00083707 Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT00083707 Completed University of Arkansas NA
NCT00082784 Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms https://ClinicalTrials.gov/show/NCT00082784 Completed National Cancer Institute (NCI) 2012-10-31
NCT00004107 Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT00004107 Completed Garden State Cancer Center at the Center for Molecular Medicine and Immunology 2001-05-31
NCT00005799 Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer https://ClinicalTrials.gov/show/NCT00005799 Completed Fred Hutchinson Cancer Research Center 2002-07-31
NCT00078858 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00078858 Completed Fred Hutchinson Cancer Research Center 2006-01-31
NCT00005609 Rituximab in Treating Patients With Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT00005609 Completed National Cancer Institute (NCI) NA
NCT00004889 Rituximab in Treating Patients With Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT00004889 Completed Jonsson Comprehensive Cancer Center 2002-01-31
NCT00075478 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer https://ClinicalTrials.gov/show/NCT00075478 Completed Fred Hutchinson Cancer Research Center 2014-02-28
NCT00073918 Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00073918 Completed Fred Hutchinson Cancer Research Center 2011-10-02
NCT00072514 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT00072514 Completed Fred Hutchinson Cancer Research Center 2008-07-31
NCT00068315 Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT00068315 Completed National Cancer Institute (NCI) 2008-12-31
NCT00003210 Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin’s Lymphoma or Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00003210 Completed National Cancer Institute (NCI) 2003-11-30
NCT00064246 Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder https://ClinicalTrials.gov/show/NCT00064246 Completed National Cancer Institute (NCI) 2004-09-30
NCT00062244 Oblimersen in Treating Patients With Relapsed or Refractory Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT00062244 Completed National Cancer Institute (NCI) 2007-06-30
NCT00058240 Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma https://ClinicalTrials.gov/show/NCT00058240 Completed National Cancer Institute (NCI) 2009-02-28
NCT00058227 Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00058227 Completed National Cancer Institute (NCI) 2009-02-28
NCT00054639 Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00054639 Completed National Cancer Institute (NCI) 2010-01-31
NCT00054483 Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction https://ClinicalTrials.gov/show/NCT00054483 Completed National Cancer Institute (NCI) 2009-09-30
NCT00049504 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer https://ClinicalTrials.gov/show/NCT00049504 Completed Fred Hutchinson Cancer Research Center 2011-03-31
NCT00045695 Bortezomib in Treating Patients With Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT00045695 Completed National Cancer Institute (NCI) 2006-03-31
NCT00040846 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT00040846 Completed Fred Hutchinson Cancer Research Center 2009-12-31
NCT00025415 Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00025415 Completed National Cancer Institute (NCI) 2005-01-31
NCT00020800 Rituximab Plus Fludarabine in Treating Patients With Waldenstrom’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT00020800 Completed Jonsson Comprehensive Cancer Center 2003-04-30
NCT00017381 Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00017381 Completed National Cancer Institute (NCI) 2007-12-31
NCT00014235 Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00014235 Completed Fred Hutchinson Cancer Research Center 2005-02-28
NCT00006473 Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00006473 Completed National Cancer Institute (NCI) 2006-02-28
NCT00005579 Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom’s Macroglobulinemia, or Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT00005579 Completed National Cancer Institute (NCI) NA
NCT00398710 A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenström’s Macroglobulinemia https://ClinicalTrials.gov/show/NCT00398710 Completed AEterna Zentaris 2011-08-31

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT00039676 Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer https://ClinicalTrials.gov/show/NCT00039676 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT02269592 Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome https://ClinicalTrials.gov/show/NCT02269592 Recruiting Dana-Farber Cancer Institute 2024-12-31
NCT03521596 Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström’s Macroglobulinemia and in IgM-MGUS https://ClinicalTrials.gov/show/NCT03521596 Recruiting Fondazione Italiana Linfomi ONLUS 2020-03-31
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31
NCT01177527 Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom Macroglobulinemia and Related Disorders https://ClinicalTrials.gov/show/NCT01177527 Active, not recruiting Dana-Farber Cancer Institute 2021-01-31
NCT00923507 Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) https://ClinicalTrials.gov/show/NCT00923507 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT00919139 S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS. https://ClinicalTrials.gov/show/NCT00919139 Completed Southwest Oncology Group 2010-11-30

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02298816 B-Cell Hematologic Malignancy Vaccination Registry https://ClinicalTrials.gov/show/NCT02298816 Enrolling by invitation Aurora Health Care 2024-12-31